UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 14, 2006
DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
New Jersey 0-19777 22-3103129
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification Number)
25 Upton Drive
Wilmington, Massachusetts 01887
(Address of principal executive offices, including ZIP code)
(978) 657-7500
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Securities Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 - Entry into a Material Definitive Agreement.
On February 14, 2006, the Compensation Committee of the Board of Directors
of DUSA Pharmaceuticals, Inc. (the "Company") held its regularly scheduled
annual compensation review meeting for 2005 and approved the following
compensatory arrangements for the Company's "named executive officers" (as
defined in Item 402(a)(3) of Regulation S-K):
Executive Officer 2005 Cash Bonus 2006 Salary
----------------- --------------- -----------
D. Geoffrey Shulman, Chief Executive Officer and
Chairman of the Board $141,920 $416,000
Robert F. Doman, President and
Chief Operating Officer $ 85,150 $312,000
Stuart L. Marcus, Vice President, Scientific
Affairs and Chief Medical Officer $ 52,750 $269,100
Paul A. Sowyrda, Vice President, Marketing $ 36,580 $206,000
Scott L. Lundahl, Vice President, Regulatory
Affairs and Intellectual Property $ 38,550 $197,600
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DUSA PHARMACEUTICALS, INC.
Dated: February 21, 2006 By: /s/ D. Geoffrey Shulman
-------------------------------
D. Geoffrey Shulman, MD, FRCPC
Chairman of the Board and Chief
Executive Officer